Clinical trial
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced…
NCT00080353 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00080353 |
|---|---|
| Title | Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma |
| Official title | Phase II Study in Metastatic Melanoma Using Lymphocytes Reactive With the gp100 Antigen and Immunization Using a Recombinant rF-gp100P209 Virus Encoding a gp100 Peptide Following a Nonmyeloablative Lymphocyte Depleting Regimen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | IL-2, gp100:209-217, OKT3, rF-go 100P209, Montanide ISA 51 |
| Enrollment | 58 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | Mar 29, 2004 |
| Last update posted | Jun 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: